[Neoadjuvant chemotherapy in sarcoma].
This document describe s the proposed clinical practices guidelines for neoadjuvant chemotherapy in soft tissue sarcomas proposed by the French Sarcoma Group.Neo-adjuvant chemotherapy remains an experimental therapeutic procedure in soft tissue sarcomas. Neo-adjuvant chemotherapy may be proposed in three different types of situations: 1) a locally advanced tumor, non accessible to R0 or 1 removal of the lesion. Its objective is there to allow for R0 or R1 surgical removal of the tumor. 2) A locally advanced tumor, accessible to R0 or 1 removal of the lesion, but with a mutilating surgery (amputation). Its objective is there to allow for R0 or R1 conservative surgical removal of the tumor. In both situation, the strategy should be discussed beforehand in a multidisciplinary specialized consultation for sarcoma. 3) In the case where complete (R0 or R1) surgical removal of the tumor can be performed, neooadjuvant chemotherapy has no demonstrated role. The only randomized phase III clinical trial testing neo-adjuvant chemotherapy in this setting, i.e. the STBSG 62871 STBSG trial, failed to demonstrate any benefit in terms of overall or progression free survival. The selection of the type of chemotherapy regimen given in the neoadjuvant setting should be discussed in a multidisciplinary setting, considering the age and the general status of the patient; young patients, without associated concomittent illnesses should be proposed for a combined chemotherapy regimen, combining doxorubicin (> or = 50 mg/m2) and ifosfamide (> 5 g/m2) on the basis of randomized trials demonstrating an improvement of response rate versus single agent therapy with doxorubine. In elderly and/or frail patients, conversely, single agent doxorubicin may be the preferred option.
Blay
Jean-Yves
JY
Hôpital Edouard-Herriot et Unité Inserm U590, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon. blay@lyon.fnclcc.fr
Bonvalot
Sylvie
S
Fayette
Jérôme
J
Stockle
Eberhart
E
Ray-Coquard
Isabelle
I
Coindre
Jean-Marie
JM
Duffaud
Florence
F
Taieb
Sophie
S
Sunyach
Marie-Pierre
MP
Ranchere
Dominique
D
Meeus
Pierre
P
Le Cesne
Axel
A
Bui
Binh Nguyen
BN
D000970:Antineoplastic Agents / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D003131:Combined Modality Therapy / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D020360:Neoadjuvant Therapy / Q000379:methods*; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin